CDK1抗体

+ +

•  

   

     Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng);    

  
  

•  

   

     Western blot analysis using CDK1 mouse mAb against Hela (1), Jurkat (2), K562 (3), A431 (4), MCF-7 (5), RAW264.7 (6), NIN/3T3 (7), PC-12 (8), and Cos7 (9) cell lysate.    

  
  

CDK1 (Cyclin-Dependent Kinase 1), also known as Cdc2. is a critical serine/threonine kinase that regulates cell cycle progression, particularly the G2/M phase transition and mitotic entry. It forms a complex with cyclin B, and its activity is tightly controlled by phosphorylation/dephosphorylation events and checkpoint pathways to ensure genomic stability. Dysregulation of CDK1 is linked to various diseases, including cancer, where its overexpression often correlates with uncontrolled proliferation and poor prognosis.

CDK1 antibodies are essential tools in biomedical research, enabling the detection, localization, and functional analysis of CDK1 in cells and tissues. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry to study CDK1 expression levels, cell cycle dynamics, and interactions with regulatory proteins. Specificity and validation are crucial, as cross-reactivity with other CDK family members (e.g., CDK2. CDK4) may occur. High-quality CDK1 antibodies help identify its role in cancer mechanisms, drug resistance, and therapeutic targeting. For instance, they are employed to evaluate CDK1 inhibition strategies or biomarkers in oncology research. However, variability in experimental outcomes due to antibody clones, sample preparation, or tissue types necessitates careful optimization and controls. Overall, CDK1 antibodies remain indispensable for advancing our understanding of cell cycle regulation and its implications in disease.